New Pill Doubles Survival Time in Advanced Pancreatic Cancer Trial
Similar Articles
Experimental Pill Doubles Survival Time in Advanced Pancreatic Cancer Trial
Pancreatic Cancer Survival Advances Through New Drugs and Vaccines
Personalized mRNA Vaccine Shows Sustained Benefit in Melanoma Patients After Five Years
Early Treatment May Postpone Rheumatoid Arthritis Onset by Years
Pre-Surgery Immunotherapy Shows Promise for a Subtype of Colorectal Cancer
A new daily pill called daraxonrasib has doubled survival time for patients with advanced pancreatic cancer in a major clinical trial. Patients taking the drug lived for an average of 13.2 months, compared to 6.6 to 6.7 months for those on standard chemotherapy. The drug targets a common cancer-driving mutation and could represent a significant advance for a disease with a very low survival rate.
Facts First
- Daraxonrasib doubled average survival to 13.2 months in a 500-patient trial for advanced pancreatic cancer.
- The drug targets the KRAS protein, a mutation present in over 90% of the most common pancreatic cancers.
- Standard chemotherapy survival in the trial averaged 6.6 to 6.7 months.
- Advanced pancreatic cancer has a five-year survival rate of about 3% and often spreads before diagnosis.
- Similar KRAS-targeting drugs are now being tested in trials for lung and colon cancers.
What Happened
Researchers presented results from a 500-patient trial of a new daily pill, daraxonrasib, at the American Society of Clinical Oncology (ASCO) annual meeting. The trial, led by the Dana-Farber Cancer Institute, involved patients whose pancreatic cancer had spread. Patients taking daraxonrasib lived for an average of 13.2 months, while those receiving standard chemotherapy lived for an average of 6.6 to 6.7 months.
Why this Matters to You
Pancreatic cancer is often diagnosed after it has spread, and the five-year survival rate for advanced cases is approximately three percent. This new treatment could significantly extend life for many patients facing this aggressive disease. If approved, daraxonrasib may offer a new, more effective option for the over 90 percent of patients with the most common form of pancreatic cancer who carry a KRAS mutation. The drug's mechanism works regardless of the specific KRAS variant, meaning it could potentially benefit a broad group of patients.
What's Next
The success of daraxonrasib in pancreatic cancer may accelerate its development and the testing of similar drugs for other cancers driven by KRAS mutations, which are present in roughly one-third of all human tumors. Similar drugs are already in trials for lung and colon cancers. Further research and regulatory review will be needed before daraxonrasib becomes widely available to patients.